$LIXT News Article - Inactivating Mutations in Sca
Post# of 31
(Total Views: 228)
Posted On: 03/22/2022 8:40:53 AM
$LIXT News Article - Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology's Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy https://marketwirenews.com/news-releases/inac...63163.html
(0)
(0)Lixte Biotechnology Holdings, Inc. (LIXT) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼